Health Claims Substantiation
Evidence standards and regulatory controls for efficacy, safety, and comparative claims made for OTC medicines, cosmetics, supplements, and consumer health products.
Foresight tracks Health Claims Substantiation developments and surfaces the alerts most likely to matter before they turn into missed deadlines, recalls, or escalation work.
Current activity
Steady
In line with the prior 8-week baseline
3-month trend
Latest alerts below
Last updated
4 April 2026, 10:32
Latest Health Claims Substantiation alerts
The most recent regulatory and guidance signals tracked by Foresight
Bavarian Higher Administrative Court Confirms OMEGAlife Omega-3 Product Is a Food Supplement, Not a Medicinal Product
The Bavarian Higher Administrative Court ruled in March 2026 that Omega-3 supplements with nutrient levels achievable through a standard diet are classified as food supplements, not medicinal products. This decision reinforces strict thresholds for 'functional medicinal product' status in Germany, impacting reimbursement eligibility and requiring manufacturers to demonstrate unique metabolic effects to avoid food-law restrictions.
GermanyJapan CAA Confirms 31 March 2026 Reporting Deadline and Enforcement for Functional Claims Foods
Japan’s Consumer Affairs Agency has confirmed a strict March 31, 2026, deadline for mandatory self-check reporting on functional claims foods, with non-compliant products facing public database flagging and enforcement actions. Companies must ensure all outstanding reports are submitted immediately to avoid administrative orders for improper labeling and the loss of market access for functional health claims.
JapanChina SAMR Orders Half-Year Cleanup of Prompt Language in Advertising
China's SAMR has launched a six-month enforcement campaign (March–September 2026) targeting misleading "small print" and inadequate risk disclosures in advertising. Businesses must ensure that statutory warnings and limiting conditions for complex or regulated products are prominent to avoid penalties and potential product-level enforcement.
ChinaUS FDA Issues Online Advisory Letter to Divine Rx Nutrition for Disease-Claim Supplements
The FDA has issued an advisory letter to Divine Rx Nutrition for marketing supplements with unapproved disease-treatment claims, classifying them as illegal new drugs. This action signals continued aggressive enforcement against online health-claim violations, requiring firms to strictly audit digital marketing and labeling to mitigate regulatory risk.
United StatesUS FDA Issues Online Advisory Letter to Bodynplant Over Unapproved Serious Disease Treatment Claims
The US FDA has issued an enforcement advisory against an online retailer for marketing unapproved products with claims to treat serious diseases such as cancer and HIV. This action underscores the FDA's aggressive monitoring of digital health claims, necessitating immediate audits of e-commerce marketing and labeling to mitigate enforcement and reputational risks.
United StatesNetherlands Council Of State Refers Food Supplement–Medicine And Online Review Questions To CJEU (ECLI:NL:RVS:2026:1651)
The Dutch Council of State has referred questions to the CJEU to clarify the legal boundary between food supplements and medicinal products, specifically focusing on whether online consumer reviews can trigger a reclassification. This case will determine if retailers can be held liable under pharmaceutical laws for user-generated content and whether products clearly defined as supplements can be legally treated as medicines based solely on digital presentation.
Netherlands
European UnionBrazilian Chamber Working Group Backs Urgent Bills to Tighten Sanitary Control of Dietary Supplements
Brazilian lawmakers have recommended an urgent legislative procedure to tighten sanitary controls and increase penalties for dietary supplement fraud. Manufacturers should prepare for mandatory QR-code traceability, stricter online sales liability, and potential criminalization of non-compliance as Brazil shifts away from notification-based oversight.
BrazilUK Department of Health and Social Care Updates ACBS Application Guidance and Submission Deadlines
The UK has updated submission deadlines and transitioned to a fully digital application process for the Advisory Committee on Borderline Substances (ACBS) through 2027. Manufacturers of medical foods and specialized supplements must align product listing strategies with these fixed windows to ensure timely NHS Drug Tariff inclusion and market access.
United KingdomBrazil ANVISA Seizes Irregular Health Products At Mercado Livre Warehouse
Brazil’s ANVISA has escalated enforcement against irregular health and cosmetic products, conducting a major seizure at a leading e-commerce fulfillment center in March 2026. This move establishes a precedent for platform-level accountability, requiring manufacturers and distributors to ensure strict compliance with local registration and labeling standards to avoid supply chain disruptions.
BrazilVietnam Abolishes Pre-Market Approval for Cosmetic Advertising
Vietnam has abolished the pre-market approval requirement for cosmetic advertising content, effective February 15, 2026. This shift to a post-market surveillance model requires businesses to strengthen internal self-assessment and maintain rigorous claim-substantiation files to mitigate enforcement risks.
VietnamJapan Consumer Affairs Agency Publishes Settlement of Consumer Group Injunction on LISTERINE “No.1” Bactericidal Claims
Japan’s Consumer Affairs Agency has finalized a settlement regarding misleading "No.1" bactericidal efficacy claims on consumer product labeling. This enforcement signals heightened scrutiny of superlative marketing, requiring that performance claims be substantiated by prominent and unambiguous data to avoid "superior quality misrepresentation" risks.
JapanColorado Bill SB26-066 Would Regulate Compounded Weight-Loss Medications
Colorado is advancing SB26-066 to establish strict oversight and labeling requirements for non-FDA-approved compounded weight-loss medications. Impacted firms must prepare for rigorous ingredient traceability and advertising restrictions to mitigate significant financial penalties and licensing risks.
United StatesUS District Court (New Jersey) Dismisses PFAS Consumer Suit Against Band-Aid For Lack Of Standing
A US Federal Court dismissed a consumer class action alleging PFAS contamination in Band-Aid products, citing a lack of concrete injury or specific misrepresentation. The decision sets a high bar for PFAS-related "benefit of the bargain" claims, suggesting that general safety marketing is insufficient to establish legal standing without evidence of actual harm.
United StatesEFSA NDA Panel Finds Insufficient Evidence for Anxiofit‑1 Article 14 Health Claim on Anxiety Reduction
EFSA has rejected a disease risk-reduction health claim for Anxiofit-1 (Echinacea angustifolia extract), citing insufficient evidence to link its consumption with reduced anxiety. Manufacturers of botanical supplements should anticipate stricter scrutiny of clinical data for Article 14 claims and ensure long-term efficacy studies are robust before seeking EU market authorization.
European UnionEU Parliament Questions Commission on Energy Powders for Inhalation (P-000828/2026)
The European Commission has been formally questioned regarding the regulatory status and safety of 'energy powders for inhalation,' signaling potential scrutiny of products that currently bypass traditional food or drug classifications. Manufacturers of novel stimulant delivery systems should anticipate increased market surveillance and potential legislative action to close regulatory gaps, particularly concerning minor protection and health claim substantiation.
European UnionBrazil Anvisa Orders Seizure of Palmito Lemos Palm-Heart Products and Recall of Melatonin Sublingual Drops
Brazil's ANVISA has ordered the immediate seizure of Palmito Lemos canned palm hearts and the recall of specific melatonin supplements following inspections that revealed critical manufacturing and safety violations. These enforcement actions signal intensified market surveillance on food safety and supplement claims, requiring immediate supply chain intervention to mitigate legal and reputational risks.
BrazilKorea Cosmetics Association Announces Planned Amendment to Cosmetics Act on Labelling and Environmental Claims
South Korea is preparing an amendment to the Cosmetics Act to tighten requirements for product labeling and environmental or efficacy claims. Companies should anticipate stricter substantiation standards for green marketing and performance claims to mitigate legal and reputational risks in the Korean market.
South KoreaKorea MFDS Outlines 2027 Periodic Re-evaluation Programme For Health Functional Food Ingredients
South Korea’s MFDS has announced 31 functional ingredients, including amino acids and botanicals, for its 2027 periodic safety and efficacy re-evaluation. Recognition holders should prepare updated substantiation data by late 2026 to mitigate risks of restricted usage, revised health claims, or potential market withdrawal.
South KoreaSwedish Food Agency Consultation on Kontrollwiki Guidance for Generic Descriptions (Dnr 2026/01128)
The Swedish Food Agency is consulting on updated guidance for "generic descriptions" in food labeling, with feedback due by March 23, 2026. This update clarifies the criteria for maintaining traditional product names that allude to health benefits, allowing businesses to protect established branding without meeting the rigorous substantiation requirements of the EU Nutrition and Health Claims Regulation.
SwedenBrazil ANVISA Publishes Documents for Simplified Registration of Herbal Medicines
Brazil's ANVISA has launched a revised regulatory framework for herbal medicines, introducing updated monographs and simplified registration documents effective February 2026. Companies must update registration dossiers and product labeling to align with these plant-specific standards, which replace more rigid synthetic drug requirements to facilitate market entry.
BrazilNot a newsletter. Not a feed.
Structured intelligence mapped to your business.
These are just a few of the most recent Health Claims Substantiation alerts. Foresight tracks every jurisdiction, every day — and surfaces only what affects your portfolio, with full citations and evidence.
Book a demoFrequently asked questions
Everything you need to know about Foresight's regulatory intelligence platform
Still have questions? Get in touch with our team
Join 3,500+ professionals staying ahead
Subscribe to Foresight Weekly for expert-picked regulatory developments across chemicals, sustainability, product safety, ESG, and HSE.
Free forever. Unsubscribe anytime.
Read by professionals at
